Cargando…

Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients

The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The double emulsion solvent evaporation technique using aminoalkyl methacrylate copo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutthapitaksakul, Lalinthip, Thanawuth, Kasitpong, Dass, Crispin R., Sriamornsak, Pornsak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309182/
https://www.ncbi.nlm.nih.gov/pubmed/34371737
http://dx.doi.org/10.3390/pharmaceutics13071046
_version_ 1783728462338457600
author Sutthapitaksakul, Lalinthip
Thanawuth, Kasitpong
Dass, Crispin R.
Sriamornsak, Pornsak
author_facet Sutthapitaksakul, Lalinthip
Thanawuth, Kasitpong
Dass, Crispin R.
Sriamornsak, Pornsak
author_sort Sutthapitaksakul, Lalinthip
collection PubMed
description The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The double emulsion solvent evaporation technique using aminoalkyl methacrylate copolymer (AMC) was used to prepare taste-masked microparticles. Factors affecting the quality of the taste-masked microparticles were analyzed using an Ishikawa diagram. A risk-ranking approach was used to rank the formulation and process risks. Furthermore, the effect of AMC quantity, stirring time, and volume of outer water phase on various responses, such as particle size, the amount of drug dissolved at 5 min (Q(5)) in simulated saliva fluid, and mean dissolution time (MDT) in simulated gastric fluid, was investigated using the Box-Behnken design. The optimized microparticles were then used to prepare orally disintegrating tablets (ODTs) and evaluated by in vitro and in vivo testing. The results demonstrated that particle size was influenced by the AMC amount and stirring time. Q(5) was significantly affected by the amount of AMC and the volume of the outer water phase. On the other hand, these two factors had a positive effect on MDT. The optimized microparticles had a particle size of 174.45 ± 18.19 µm, Q(5) of 5.04%, and MDT of 5.97 min. The ODTs with taste-masked microparticles showed acceptable in vitro dissolution with an MDT of 5 min. According to the results of a panel of six human volunteers, they greatly improved palatability.
format Online
Article
Text
id pubmed-8309182
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83091822021-07-25 Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients Sutthapitaksakul, Lalinthip Thanawuth, Kasitpong Dass, Crispin R. Sriamornsak, Pornsak Pharmaceutics Article The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The double emulsion solvent evaporation technique using aminoalkyl methacrylate copolymer (AMC) was used to prepare taste-masked microparticles. Factors affecting the quality of the taste-masked microparticles were analyzed using an Ishikawa diagram. A risk-ranking approach was used to rank the formulation and process risks. Furthermore, the effect of AMC quantity, stirring time, and volume of outer water phase on various responses, such as particle size, the amount of drug dissolved at 5 min (Q(5)) in simulated saliva fluid, and mean dissolution time (MDT) in simulated gastric fluid, was investigated using the Box-Behnken design. The optimized microparticles were then used to prepare orally disintegrating tablets (ODTs) and evaluated by in vitro and in vivo testing. The results demonstrated that particle size was influenced by the AMC amount and stirring time. Q(5) was significantly affected by the amount of AMC and the volume of the outer water phase. On the other hand, these two factors had a positive effect on MDT. The optimized microparticles had a particle size of 174.45 ± 18.19 µm, Q(5) of 5.04%, and MDT of 5.97 min. The ODTs with taste-masked microparticles showed acceptable in vitro dissolution with an MDT of 5 min. According to the results of a panel of six human volunteers, they greatly improved palatability. MDPI 2021-07-09 /pmc/articles/PMC8309182/ /pubmed/34371737 http://dx.doi.org/10.3390/pharmaceutics13071046 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sutthapitaksakul, Lalinthip
Thanawuth, Kasitpong
Dass, Crispin R.
Sriamornsak, Pornsak
Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
title Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
title_full Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
title_fullStr Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
title_full_unstemmed Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
title_short Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
title_sort optimized taste-masked microparticles for orally disintegrating tablets as a promising dosage form for alzheimer’s disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309182/
https://www.ncbi.nlm.nih.gov/pubmed/34371737
http://dx.doi.org/10.3390/pharmaceutics13071046
work_keys_str_mv AT sutthapitaksakullalinthip optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients
AT thanawuthkasitpong optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients
AT dasscrispinr optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients
AT sriamornsakpornsak optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients